Literature DB >> 22437202

Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias.

Alexander Khlebtovsky1, Amihai Rigbi, Eldad Melamed, Ilan Ziv, Israel Steiner, Alona Gad, Ruth Djaldetti.   

Abstract

Parkinson's disease (PD) exacts a physical and emotional toll on both patients and family. The aim of this study was to compare patient and caregiver perceptions of the social consequences of basic symptoms of PD and levodopa-induced dyskinesias. Forty patients with PD and dyskinesias and 35 of their caregivers completed a self-report questionnaire on the impact of PD and dyskinesias on their feelings of security and embarrassment and participation in family/social events, and indicated their preference for the "on" (with dyskinesias) or the "off" (without dyskinesias) state. The patients scored significantly higher than the caregivers did on the negative social impact of the disease in general (p = 0.002) and of the dyskinesias in particular (p = 0.03). Nevertheless, the patients expressed a significantly greater preference for the "on" state (83 %) than the caregivers (59 %) (p = 0.03). Preferences turned to be reverse in direction among spouse-caregivers who significantly preferred the "off" state (54 %) than the patients (25 %) (p = 0.04). Although patients have a worse perception of the effects of PD than their caregivers do, they prefer the more independent "on" state, whereas their caregivers prefer the "off" state.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22437202     DOI: 10.1007/s00702-012-0796-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  15 in total

1.  Development of a measure of the impact of chronic parental illness on adolescent and adult children. The parental illness impact scale (Parkinson's disease).

Authors:  Anette Schrag; David Morley; Niall Quinn; Marjan Jahanshahi
Journal:  Parkinsonism Relat Disord       Date:  2004-10       Impact factor: 4.891

2.  Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.

Authors:  M Péchevis; C E Clarke; P Vieregge; B Khoshnood; C Deschaseaux-Voinet; G Berdeaux; M Ziegler
Journal:  Eur J Neurol       Date:  2005-12       Impact factor: 6.089

3.  Do motor and nonmotor symptoms in PD patients predict caregiver strain and depression?

Authors:  Julie H Carter; Barbara J Stewart; Karen S Lyons; Patricia G Archbold
Journal:  Mov Disord       Date:  2008-07-15       Impact factor: 10.338

Review 4.  A review of the health-related quality of life and economic impact of Parkinson's disease.

Authors:  Clare H Dowding; Claire L Shenton; Sam S Salek
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

5.  Predictors of depressive symptoms among spouse caregivers in Parkinson's disease.

Authors:  H H Fernandez; R E Tabamo; R R David; J H Friedman
Journal:  Mov Disord       Date:  2001-11       Impact factor: 10.338

6.  Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment.

Authors:  C G Goetz; G T Stebbins; H M Shale; A E Lang; D A Chernik; T A Chmura; J E Ahlskog; E E Dorflinger
Journal:  Mov Disord       Date:  1994-07       Impact factor: 10.338

Review 7.  The economic impact of Parkinson's disease.

Authors:  Leslie J Findley
Journal:  Parkinsonism Relat Disord       Date:  2007-08-16       Impact factor: 4.891

8.  Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.

Authors:  Connie Marras; Anthony Lang; Murray Krahn; George Tomlinson; Gary Naglie
Journal:  Mov Disord       Date:  2004-01       Impact factor: 10.338

Review 9.  Levodopa-induced dyskinesias.

Authors:  Giovanni Fabbrini; Jonathan M Brotchie; Francisco Grandas; Masahiro Nomoto; Christopher G Goetz
Journal:  Mov Disord       Date:  2007-07-30       Impact factor: 10.338

10.  Mutuality of the marital relationship in Parkinson's disease.

Authors:  Haruko Tanji; Karen E Anderson; Ann L Gruber-Baldini; Paul S Fishman; Stephen G Reich; William J Weiner; Lisa M Shulman
Journal:  Mov Disord       Date:  2008-10-15       Impact factor: 10.338

View more
  13 in total

Review 1.  Molecular imaging of levodopa-induced dyskinesias.

Authors:  Flavia Niccolini; Lorenzo Rocchi; Marios Politis
Journal:  Cell Mol Life Sci       Date:  2015-02-15       Impact factor: 9.261

2.  ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.

Authors:  Rajesh Pahwa; Caroline M Tanner; Robert A Hauser; Stuart H Isaacson; Paul A Nausieda; Daniel D Truong; Pinky Agarwal; Keith L Hull; Kelly E Lyons; Reed Johnson; Mary Jean Stempien
Journal:  JAMA Neurol       Date:  2017-08-01       Impact factor: 18.302

3.  Carbidopa/levodopa dose elevation and safety concerns in Parkinson's patients: a cross-sectional and cohort design.

Authors:  David W Brodell; Nicole T Stanford; Charles E Jacobson; Peter Schmidt; Michael S Okun
Journal:  BMJ Open       Date:  2012-12-11       Impact factor: 2.692

Review 4.  Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?

Authors:  Daniella Rylander Ottosson; Emma Lane
Journal:  Front Cell Neurosci       Date:  2016-02-08       Impact factor: 5.505

5.  Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).

Authors:  Wolfgang Oertel; Karla Eggert; Rajesh Pahwa; Caroline M Tanner; Robert A Hauser; Claudia Trenkwalder; Reinhard Ehret; Jean Philippe Azulay; Stuart Isaacson; Larissa Felt; Mary Jean Stempien
Journal:  Mov Disord       Date:  2017-08-21       Impact factor: 10.338

6.  Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.

Authors:  Robert A Hauser; Daniel E Kremens; Lawrence W Elmer; David L Kreitzman; Ryan R Walsh; Reed Johnson; Robert Howard; Jack T Nguyen; Rajiv Patni
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

7.  Self-reported and experimentally induced self-disgust is heightened in Parkinson's disease: Contribution of behavioural symptoms.

Authors:  Marianna Tsatali; Paul G Overton; Ana B Vivas
Journal:  PLoS One       Date:  2019-10-16       Impact factor: 3.240

8.  Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson's Disease: An Open-Label Pilot Study.

Authors:  Alexander Khlebtovsky; Israel Steiner; Therese Treves; Ruth Djaldetti
Journal:  Clin Transl Sci       Date:  2019-09-24       Impact factor: 4.689

9.  Health-related quality of life in Parkinson's disease patients in northeastern Sicily, Italy: (An ecological perspective).

Authors:  Letteria Spadaro; Lilla Bonanno; Giuseppe Di Lorenzo; Placido Bramanti; Silvia Marino
Journal:  Neural Regen Res       Date:  2013-06-15       Impact factor: 5.135

Review 10.  Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Vibhash D Sharma; Kelly E Lyons; Rajesh Pahwa
Journal:  Ther Clin Risk Manag       Date:  2018-04-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.